|
Sales Contacts
For advertising information contact: Alan El Faye
VP, Advertising Sales - CA, Western US, Canada, Pacific Rim
213-300-3886
Kay O. Christopher
Regional Sales Manager, Advertising Sales -New England, North Eastern US
860-693-2991
Tom Loughran
Regional Sales Manager, Advertising Sales -Midwest, South Eastern US, Europe
781-972-5482
|
|
Contact the Editor
We invite your comments and feedback for this edition of Predictive Biomedicine. |
|
Link to Us!
You are welcome to link to articles on our website. Contact Catherine Varmazis for details.
e-Prints & Reprints
To post a full article from Predictive Biomedicine or Bio-IT World on your website (not just a link), or for paper reprints, please contact:
Ashley Zander
The YGS Group
717-399-1900 ext.125
|
|
|
| IN THIS ISSUE |
|
Vogelstein Says Pathways Are Best Tumor Targets |
|
Pathway Tools, GeneGo Bask in Spotlight |
|
WRI Spinout: Launching Strategic Medicine Inc. |
|
Through the Ups & Downs, There is Only One IBM |
|
Short News & Analysis |
|
|
| |
Research News
Cancer Studies Suggest Pathways Are Best Targets
By John Russell
This month, two papers in Science* described the integrated genomic analysis of pancreatic cancer and a form of brain cancer, glioblastoma multiforme (GBM). They not only revealed important biology, but also suggest that the pharmaceutical and health care industries must fight solid tumors differently—principally by aiming at pathways rather than individual targets and focusing on early detection rather late-stage cures.
The studies, led by researchers from Johns Hopkins, examined roughly 20 tumors of each cancer type. More...
|
|
|
| |
Pathway Tools Shine
GeneGo Basks in the Spotlight
By John Russell
The attention being given to two recent Science papers* suggesting pathways, not single genes, are better targets for solid cancer tumor treatment is good news for all pathway tool providers. Such tools were important in this work by prominent cancer researchers, which is discussed in the lead article in this issue. The attention is especially sweet for GeneGo which provided tools and data analysis, and had two authors, Tatiana Nikolskaya (president and CSO) Yuri Nikolsky (CEO), on the papers.
It’s probably too much to declare these are heady days for pathway tool providers, but there is no denying their increasing traction inside pharma, their growing impact on research, and the soaring aspirations of the pathway tool provider camp. Currently, GeneGo, Ingenuity Systems, and Ariadne dominate the market, although there are many others. While the Science papers shone a flattering spotlight on GeneGo last month, all of the pathway tool providers are trumpeting the growing number of their citations in journals. Ingenuity, for example, touts 1000 publications in 300 journals on its website. More...
|
|
| |
Business Strategy
Launching Strategic Medicine Inc.
By John Russell
Successful technology transfer from non-profit institutions to the unforgiving commercial market is rarely easy. In life sciences, the wary investor community doesn’t particularly value technology; they mostly want compounds. When the goal is to spin out a new company, figuring out how to sever apron strings from a parent organization is often tricky, and of course there are the usual company building activities. Now, consider trying to commercialize not one, but several technology-based initiatives at roughly the same time, and you’ve put yourself in Michael Liebman’s shoes.
Liebman is president/managing director of Strategic Medicine Inc. (SMI), a 2007 spinout from the Windber Research Institute (WRI), whose rich assets include, among other things, a unique tissue repository of more than 30,000 breast samples, a huge database of breast cancer genomic and clinical data, sophisticated internally developed software, and image handling and storage expertise. More...
|
|
| |
|
Corporate Insight
There Is Only One IBM
Trying to describe in a single story the full scope of IBM’s Life Sciences and Healthcare activities and related work being done by IBM Research is at best ambitious and at worst foolhardy. Big Blue may be unique in the corporate world in terms of the sheer number, diversity, and depth of its activities. More...
|
|
Top Story Last Issue
Merck’s Eric Schadt on the Power of Integrative Genomics
Eric Schadt, the scientific executive director of genetics at Merck Research Laboratories and Merck's Rosetta Inpharmatics subsidiary, is a leading proponent of integrative genomics who is decisively proving his point by delivering novel targets to Merck – roughly one-third of Merck’s new targets in diabetes and obesity. More...
|
|
| |
| Short News & Analysis (Click to Read Full Briefs)
Entelos Reports $9.6M Revenue for First Half of 2008
Entelos (LSE: ENTL) this week reported $9.6 million in revenue for the first half of 2008 with a net loss of $2.6 million...
Genedata Screener 6.0 Released
Genedata released Screener 6.0, the latest version of its enterprise solution for high-throughput screening (HTS) and high-content screening (HCS) analysis...
Researcher to Build Predictive TB Model
Boston University researcher James Galagan plans to build a predictive model of how TB responds to different environmental conditions or pharmaceuticals...
Genstruct Hires VP of Sales
Genstruct announced the appointment of Louis Latino as VP of sales...
Perlegen Looks for Rarer Variants
Perlegen reports launching a new approach to discovering rare genetic variations and is using it in a study of women...
Compugen Finds Clusterin Antagonist
Compugen says it has discovered a novel peptide antagonist of the Clusterin protein using its DAC Blockers Discovery Platform...
Wilder Appointment in NIH
Elizabeth Wilder was appointed director of the Division of Strategic Coordination in the Office of Portfolio Analysis and Strategic Initiatives...
BioMerieux Buys AvariaDx for $60M
BioMérieux, a provider of in vitro diagnostics, acquired the privately held AviaraDx, a molecular in vitro diagnostics company, based in San Diego...
IBM and GI of Singapore Make Stem Cell Discovery
IBM and the Genome Institute of Singapore (GIS), revealed findings this week from a joint research study that provides new information on how stem cell differentiation is controlled by microRNAs...
LabKey Joins Bio-IT Alliance
LabKey Software, a provider of open source collaboration software, joined the Microsoft BioIT Alliance, an association of life science organizations and informatics companies...
(Click to Read Full Briefs)
|
| |
LIFE SCIENCE JOBS
Lilly Singapore Center for Drug Discovery (LSCDD) - Associate Director of Informatics,
Lead and mentor a strong team for the Bioinformatics group at the Integrative Computational Sciences (ICS) department at LSCDD towards the development of novel algorithms, data analysis methods and software tools for drug discovery. Work closely with the Software Engineering group at ICS, and collaborate with the Discovery IT organization in Europe and USA. For additional information, or to apply visit: LSCDD
Lilly Singapore Center for Drug Discovery (LSCDD)- Senior Bioinformatics Scientist,
Contribute to the development of novel algorithms, data analysis methods and software tools for drug discovery as part of the Integrative Computational Sciences (ICS) department at LSCDD. Work closely with informatics and software engineering peers at ICS, and collaborate with the Discovery IT organization in Europe and USA. The successful candidate will offer hands-on insight and expertise in tailored therapeutic informatics and statistical analyses at the post-genomic era. For additional information, or to apply visit: LSCDD
Lilly Singapore Center for Drug Discovery (LSCDD) - Manager, Software Engineering (Integrative Computational Sciences)
Join the Integrative Computational Sciences (ICS) department at Lilly Singapore Centre for Drug Discovery (LSCDD),as Manager Software Engineering. Lead the development of integrated applications to process and visualize data from cutting edge technologies used by scientists at Lilly Research Labs (LRL) and the Drug Discovery Research (DDR) teams. Masters in Computer Science/Engineering or related discipline, 10+ years post graduation experience , 2 years management experience needed. For a complete job description and requirements or to apply visit: LSCDD
Lilly Singapore Center for Drug Discovery(LSCDD) -Senior Software Engineer,
Join a strong team of software engineers in our Integrative Computational Sciences (ICS) at LSCDD. Collaborate with, and help develop integrated applications to process and visualize data from cutting-edge technologies used by scientists at Lilly Research Labs (LRL) and the Drug Discovery Research (DDR) teams. The Software Engineering team provides computational tools and tailored software solutions that enable the global effort of Tailored Therapeutics; ‘The Right Drug, at The Right Dose for The Right Patient at The Right Time'. For additional information, or to apply visit: LSCDD
Merck ~Sr. Computational Biologist
Apply and develop computational biology/informatics techniques to support Oncology drug discovery; collaborate with scientists to develop in-depth understanding of deregulated signaling pathways, discover novel targets and treatment strategies, and identify associated candidate biomarkers. Ph.D. in Computational Biology/Bioinformatics, solid statistics background and hands-on modeling and informatics techniques related to drug discovery experience required. Click to Apply
More Life Science Jobs ~ Add a Job Listing
|
|
| |
| |
FEATURED EVENTS
DIA 2nd Annual Clinical Forum: Data Driven Drug Development Decisions - October 20-23, 2008 | Ljubljana, Slovenia
Harvard Biomed HPC Leadership Summit 2008, October 5~7, 2008, Boston, MA USA
Drug Stability Reporting (eStability) Working Group Vendor Meeting - October 7, 2008.
The Fifteenth Annual Biopharmaceutical Applied Statistics Symposium - Nov 3-7,2008~ Savannah, GA
The Next Tool for Healthcare Innovation - A Complimentary Frost & Sullivan eBroadcast, Nov 20, 2008 2pm EST
Frost & Sullivan’s Medical Devices 2009 Executive MindXchange March 8-10 2009, San Francisco, CA
Barnett Educational Services, 2008 Schedule
To have your event featured here, contact Lynn Cloonan for more information.
|
|
|
|
Dear CHI Member:
Professionals like you are working to reduce dependence on trial and error and to adopt more data-driven predictive methods in drug discovery and development—and even healthcare delivery.
As a member of the CHI community, we’d like to provide you with this FREE subscription, delivered twice monthly, to Predictive Biomedicine eNewsletter, which will cover the development and use of informatics and computational tools used to manage, present, and interpret experimental data as well as those used in modeling and bio-simulation.
We hope you find its content useful and interesting; however you may easily opt out by referencing the footer of any issue. We also encourage you to extend this free subscription offer to colleagues who have interests in informatics tools & strategies driving decisions.
|
| |
| GUEST COMMENTARY |
Nothing Ventured
A September (2008) to Remember
By Michael Greeley
Did you just see that? If you blinked, you missed what was perhaps the most extraordinary week in our generation’s financial history. As awful as the week started, it ended on an emotional high. By the time you read this the market will have undoubtedly gyrated wildly again – probably many times over.
It has been shown over the many investment cycles that some of the most compelling companies are born in the most turbulent of economic times. As bad as it is now, economic cycles do just that – cycle. Venture capitalists (VCs) by profession accept significant investment risk every day; the good investors will have appropriately long horizons but will insist that value is being created all along the way. More...
Michael Greeley is a general partner at Flybridge Capital Partners, an early-stage venture capital firm based in Boston, and chairman of the New England Venture Capital Association. He can be reached at: [email protected]
|
|
| FEATURED CONTENT |
Managed Innovation,
Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
sponsored by SAS
Discovery organizations are identifying a lot of promising compounds, but clinical research processes haven't kept pace with timely testing of all those potential therapies. This white paper describes how SAS Drug Development supports true innovation across the clinical trial process.
In this white paper you will learn how to:
~Assemble data to foster better collaboration
~Get up-to-date information during clinical trials
~Make informed decisions earlier in the trial process
Download now
Addressing Life Sciences Constantly Growing Data Challenges Research Environments sponsored by BlueArc
The continued explosion of raw experimental data, the increased use of video, the growingadoption of new data retention practices, and the move to high throughput computational workflows are all placing new demands on the way life sciences organizations store and manage their data.
Download this white paper to learn about:
• Factors driving the data explosion in the life sciences
• New data management issues that must be addressed
• HPC trends that are placing new demands on storage
• Storage solution attributes that address performance, manageability, and energy efficiency. Download now
“Storage for Science – Methods for Managing Large and Rapidly Growing Data Stores in Life Science Research Environments” sponsored by Isilon
Large and rapidly growing stores of file-based and other data are a hallmark of life science research and bioinformatics. Determining how best to manage those data stores has become a significant challenge for Researchers and IT Pros alike. This paper is intended to: Provide guidance on the many storage requirements common to Life Science research; Explain the evolution of modern storage architectures; Summarize the major data storage architectures currently in use. Additionally, it will present the Isilon IQ clustered storage product as a strong and flexible solution to those needs. Download now
Microsoft’s BioIT Alliance
Bio-IT World published a special supplement with support from Microsoft and their Alliance members. The supplement provides insight into the activities of the Alliance and their partners. Click here to access the Supplement PDF.
To have your white paper featured here, contact Lynn Cloonan for more information.
|
|
| EXCLUSIVE WEBCAST |
NEW! Life Science Webcasts from Bio-IT World and Cambridge Healthtech Media Group
Bio-IT World Expo
Video Highlights
Personalized Genetics: Advancements and Driving Change
Linda Avey, co-founder of 23andMe, delivers her keynote at the 2008 Bio-IT World Conference & Expo in Boston, April 30, 2008.
View the webcast.
The Future of Personal Genomics
A distinguished panel of personal genomics experts discuss the future of personal genomics at the 2008 Bio-IT World Conference & Expo in Boston, April 30, 2008. They include Dietrich Stephan (co-founder, Navigenics); George Church (Harvard Medical School); Jeff Drazen (editor-in-chief, New England Journal Medicine); Fred Ledley (Bentley College); John Halamka (CIO, Harvard Medical School); and Linda Avey (23andMe). Bio-IT World Editor-in-Chief Kevin Davies moderates the discussion.
View the webcast.
|
|
| SBNL ARCHIVES |
View the Systems Biology newsletter archives here.
|
|
|